6 results
FWP
KPRX
Kiora Pharmaceuticals Inc
14 Jul 22
Free writing prospectus
5:14pm
Days 1 - 12 BID Dosing Day 20 Final Follow - up Cohort 4: KIO - 101 (0.15%) Cohort 4: Placebo Enrolled healthy volunteer s (N=24, 8/cohort) Dose
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
11 Jan 22
Regulation FD Disclosure
12:00am
volunteer s (N=24, 8/cohort) Dose Escalation Day 28 Final Follow - up Cohort 1: KIO - 101 (0.05%) Cohort 2: KIO - 101 (0.15%) Day 1 Single Treatment
8-K
EX-2.1
KPRX
Kiora Pharmaceuticals Inc
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
Governmental Authority or arbitrator in connection with the employment of any current or former applicant, consultant, volunteer, intern or independent
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
14 Sep 21
Regulation FD Disclosure
4:20pm
- 001 Treated Vehicle Control
13 PP - 001: Phase 1/2a Dry Eye Trial – Fully Enrolled Enrolled healthy volunteer s (N=24, 8/cohort) Day 28 Final
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
27 May 21
Regulation FD Disclosure
7:01am
patients expected to initiate in Q3:21 U.S. IND submission planned in Q4:21 – PP - 001 for systemic indications: Phase 1 healthy volunteer study … points over the next 12 to 18 months
6 Creating a World - Class Ocular Surface Franchise with a Deep Pipeline 1. Amendment to Healthy Volunteer Study
8-K
EX-2.1
vr7a3bm7
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
- Prev
- 1
- Next